news
QA of prostaglandin analogues for glaucoma treatment
Paper highlights trends in developing analytical procedures to assess the quality of prostaglandin analogues used to treat glaucoma.
List view / Grid view
Glaucoma
news
Drug-eluting contact lens shows potential in first-in-human study
The LLT-BMT1 drug releasing contact lens was safe, well tolerated and may have reduced the incidence of hyperaemia in an early glaucoma trial.
news
CHMP recommends five medicines for approval in latest meeting
The European Medicines Agency committee reports its November findings, including five drugs recommended for marketing authorisation.
article
How implantable systems and microparticle depot injections are meeting the needs of long-acting drug delivery
Implantable systems and microparticle depots are used in many areas of drug delivery to release medicines at a controlled rate within the body. The use of these long-acting dosage forms eliminates the need for frequent administrations via traditional routes of administration, which ensures patient compliance and results in improved outcomes.…
news
First human clinical trial to study cannabinol initiated
The first company to study cannabinol as an active pharmaceutical ingredient has launched its Phase I clinical trial.
news
EMA CHMP recommends seven medicines for approval
The EMA has suggested seven treatments to be granted marketing authorisations and also advocated indication extension for eight drugs.
news
‘Contact lens’ patch used to treat eye diseases
Researchers from Singapore have developed a contact lens patch type system to deliver drugs to the eye in order to combat various eye conditions...
news
FDA approves Vyzulta for open-angle glaucoma and ocular hypertension
The FDA has approved a New Drug Application for Vyzulta for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension....
news
US ophthalmic drugs market set to pass $34bn by 2025
Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action...
news
Amarantus forms Elto Pharma for CNS disorders and MANF Therapeutics for ophthalmology
18 April 2017 | By Niamh Marriott, Junior Editor
Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus' mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID).
news
Eye care company Alcon acquires Transcend Medical
18 February 2016 | By Victoria White
This Transcend Medical acquisition also expands Alcon's leadership in glaucoma and cataract treatment...
news
Allergan to acquire glaucoma treatment company AqueSys
4 September 2015 | By Victoria White
Allergan is to acquire AqueSys for a $300 million upfront payment and milestone payments related to AqueSys' lead development programmes, including XEN45...
news
Glaucoma treatment market value will grow moderately to $3 billion by 2023
10 June 2015 | By Victoria White
The treatment market for glaucoma will rise in value from $2.4 billion in 2013 to approximately $3 billion by 2023 across the seven major markets...
news
Isarna initiates first-in-human Phase I trial for ISTH0036 to treat advanced glaucoma
16 April 2015 | By Victoria White
Isarna has initiated the Phase I clinical trial with ISTH0036, an antisense oligonucleotide selectively targeting TGF-ß2 to treat advanced glaucoma...
news
Aerie Pharmaceuticals completes enrollment in second Phase 3 registration trial of Rhopressa
24 March 2015 | By Victoria White
Aerie Pharmaceuticals has announced the completion of enrollment in the Company’s second Phase 3 registration trial (“Rocket 2”) of Rhopressa...
